Education
About Us
Working with TipRanks
Follow Us
Inmode (INMD)
NASDAQ:INMD
INMD Stock Chart & Stats
$15.12
-$1.18(-6.78%)
At close: 4:00 PM EST
$15.12
-$1.18(-6.78%)
Day’s Range― - ―
52-Week Range$13.14 - $19.78
Previous CloseN/A
Volume968.14K
Average Volume (3M)1.10M
Market Cap
$955.72M
Enterprise Value$677.92M
Total Cash (Recent Filing)$532.31M
Total Debt (Recent Filing)$5.59M
Price to Earnings (P/E)10.5
Beta1.02
Next Earnings
May 04, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.46
Shares Outstanding63,209,152
10 Day Avg. Volume1,675,917
30 Day Avg. Volume1,103,062
Financial Highlights & Ratios
PEG Ratio-2.16
Price to Book (P/B)1.88
Price to Sales (P/S)3.35
P/FCF Ratio10.03
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue1.37
Enterprise Value/Gross Profit1.72
Enterprise Value/Ebitda4.54
Forecast
1Y Price Target
$17.67Price Target Upside16.87% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition InterestReported advanced talks with a foreign investment fund could culminate in a buyout that offers a meaningful premium to shareholders.
Demand RecoverySlightly better‑than‑expected revenue and stronger consumables sales with a higher U.S. mix point to early signs of demand recovery in lower‑cost, non‑invasive treatments.
Take-private FeasibilityStrong free cash flow combined with engagement of a financial advisor to run the sales process enhances the feasibility of a take‑private deal and may attract financial buyers.
Bears Say
Consumables And Product DemandInstalled base growth but falling handpiece and consumables sales suggest weakening end‑market usage, raising questions about sustainable revenue growth.
Earnings GuidanceGuidance for earnings per share below consensus signals softer profit expectations that can weigh on investor sentiment.
Profitability PressuresDeclines in gross and operating margins indicate mounting cost or pricing pressure that could squeeze future profitability.
InMode News
INMD FAQ
What was Inmode’s price range in the past 12 months?
Inmode lowest stock price was $13.14 and its highest was $19.78 in the past 12 months.
What is Inmode’s market cap?
Inmode’s market cap is $955.72M.
When is Inmode’s upcoming earnings report date?
Inmode’s upcoming earnings report date is May 04, 2026 which is in 81 days.
How were Inmode’s earnings last quarter?
Inmode released its earnings results on Feb 10, 2026. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.417 by $0.043.
Is Inmode overvalued?
According to Wall Street analysts Inmode’s price is currently Undervalued.
Does Inmode pay dividends?
Inmode does not currently pay dividends.
What is Inmode’s EPS estimate?
Inmode’s EPS estimate is 0.32.
How many shares outstanding does Inmode have?
Inmode has 63,209,152 shares outstanding.
What happened to Inmode’s price movement after its last earnings report?
Inmode reported an EPS of $0.46 in its last earnings report, beating expectations of $0.417. Following the earnings report the stock price went down -0.684%.
Which hedge fund is a major shareholder of Inmode?
Currently, no hedge funds are holding shares in INMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InMode Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$17.67 (16.87% Upside)
$17.67 (16.87% Upside)
Blogger Sentiment
Bullish
INMD Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 208.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.18%
12-Months-Change
Fundamentals
Return on Equity
13.53%
Trailing 12-Months
Asset Growth
-2.45%
Trailing 12-Months
Company Description
Inmode
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
INMD Company Deck
INMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call contained a mix of encouraging operational and strategic developments (record international performance, rising consumables mix, new product launches, commercial reorganization, and a strong cash position with active buybacks) alongside clear financial headwinds (full-year revenue down ~6% YoY, margin compression, significant GAAP EPS declines, lower ASPs, and conservative 2026 guidance). Management frames 2026 as a stabilization year, emphasizing product pipeline and commercial improvements as levers for recovery; however, near-term profitability and top-line growth remain under pressure from product mix shifts, tariffs/import costs, and softer North American demand.View all INMD earnings summariesINMD Stock 12 Month Forecast
Average Price Target
$17.67
▲(16.87% Upside)
Technical Analysis
Orthofix
―
AxoGen
―
Establishment Labs Holdings
―
SS Innovations International
―
Bioventus
―
Ownership Overview
―
Insiders
5.76% Mutual Funds
0.21% Other Institutional Investors
90.87% Public Companies and
Individual Investors